GlassScriptPhysician profile
Scott Christopher Sims
NPI 1568425106
$2,114.69
in general payments reported to CMS, 2019-2025
22 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $174 · 2021: $193 · 2022: $315 · 2023: $196 · 2024: $307 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649 · Education: $17.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.70 |
| Education | $17.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $528.93 | 2019-2024 | Breztri, Airsupra |
| Alexion Pharmaceuticals, INC. | $254.61 | 2019-2022 | |
| Amgen INC. | $235.78 | 2019-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $172.68 | 2019-2023 | Jynarque |
| Novo Nordisk INC | $124.45 | 2025 | Wegovy |
| Abbvie INC. | $119.97 | 2023 | Vraylar |
| Akebia Therapeutics INC | $115.61 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.26 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $69.92 | 2019-2025 | Velphoro |
| Genzyme Corporation | $69.61 | 2019-2022 | |
| Vifor Pharma, INC. | $68.25 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $45.43 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $33.21 | 2019 | |
| Mallinckrodt Hospital Products INC. | $33.12 | 2022 | |
| Mallinckrodt Enterprises LLC | $27.72 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $23.33 | 2019 | |
| Mylan Specialty L.P. | $17.64 | 2024 | Yupelri |
| Opko Pharmaceuticals, LLC | $17.57 | 2023 | Rayaldee |
| Terumo Medical Corporation | $16.28 | 2020 | |
| Calliditas Therapeutics US INC. | $14.99 | 2023 | Tarpeyo |
| Glaxosmithkline, LLC. | $13.78 | 2023 | Arexvy |
| Daiichi Sankyo INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.